Exploring the therapeutic potential of targeting JAK/STAT pathway (IL7/IL7R signaling) with small molecular inhibitors to sensitize Zeb2Tg ETP-ALL to LSD1i (GSK-LSD1). The gene discussed is KDM1A; the disease is acute lymphoblastic leukemia.